Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 875.56K | 1.72M | 3.42M | 6.58M | 5.01M |
Gross Profit | 265.90K | -3.08M | 498.15K | 2.66M | 1.14M |
EBITDA | -8.03M | -7.98M | -5.48M | -3.95M | -4.00M |
Net Income | -6.41M | -7.95M | -5.41M | -4.23M | -4.82M |
Balance Sheet | |||||
Total Assets | 2.31M | 3.50M | 5.31M | 10.35M | 8.91M |
Cash, Cash Equivalents and Short-Term Investments | 434.40K | 2.03M | 3.67M | 8.05M | 6.39M |
Total Debt | 1.83M | 963.13K | 0.00 | 0.00 | 0.00 |
Total Liabilities | 7.63M | 4.21M | 1.85M | 1.69M | 4.11M |
Stockholders Equity | -5.32M | -703.36K | 3.47M | 8.66M | 4.81M |
Cash Flow | |||||
Free Cash Flow | -2.87M | -5.83M | -4.38M | -5.86M | -3.68M |
Operating Cash Flow | -913.98K | -5.68M | -4.18M | -5.83M | -3.22M |
Investing Cash Flow | -1.94M | -289.61K | -207.44K | -26.87K | -463.58K |
Financing Cash Flow | 764.83K | 4.14M | 0.00 | 7.50M | 7.23M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | ¥355.44B | 11.35 | -2.99% | 2.49% | 11.76% | -10.21% | |
52 Neutral | $4.60M | ― | -21.29% | ― | 80.87% | 82.44% | |
46 Neutral | AU$9.77M | ― | -164.01% | ― | -18.80% | -46.65% | |
44 Neutral | AU$7.29M | ― | -55.38% | ― | -3.82% | 79.24% | |
39 Underperform | AU$4.26M | ― | ― | ― | ― |
Bod Science Limited, currently under a Deed of Company Arrangement, reported a significant increase in revenue from ordinary activities, up by 38% to $600,659 for the half-year ending December 31, 2024. The company also reported a substantial reduction in net loss, down 99.7% to $16,434, compared to the previous period. Despite these improvements, the company continues to face financial challenges with net tangible liabilities per share slightly increasing to (3.07) cents. Additionally, the dissolution of its UK subsidiary, Aqua Phase Ltd, was noted during this period.
Bod Science Limited has provided an update for the quarter ending June 30, 2025, highlighting a net cash inflow of $858k from operating activities, driven by an R&D tax incentive and contributions from Biortica. The company is under a Deed of Company Arrangement with Biortica, which involves a Share Purchase Agreement to acquire Biortica’s shares. The DOCA period has been extended to August 7, 2025, due to delays in meeting ASX requirements, with an extraordinary general meeting expected by September 30, 2025. This development is crucial for Bod’s operational continuity and strategic positioning in the cannabis drug development industry.
Bod Science Limited reported a net cash inflow from operating activities of $858,000 for the current quarter, supported by government grants and tax incentives totaling $678,000. The company experienced a net decrease in cash and cash equivalents of $26,000 over the year to date, highlighting a challenging financial environment with limited cash flow from investing and financing activities.
Bod Science Limited has announced a change in its registered office and principal place of business to a new address in Sydney, Australia. This move, approved by the Deed Administrator, reflects the company’s ongoing restructuring efforts under a Deed of Company Arrangement. The change is part of Bod’s strategic initiatives to strengthen its operational framework and potentially improve its market positioning.
Bod Science Limited has announced a change in its company secretary, with Carlie Hodges resigning and Joanne Patterson being appointed as her replacement. This change occurs as the company continues to operate under a Deed of Company Arrangement, reflecting ongoing restructuring efforts. The appointment of a new company secretary may impact the company’s administrative operations and stakeholder relations as it navigates its current financial and strategic challenges.